Efficacy of ticarcillin/clavulanate was studied in the treatment of 11 patients with severe community- and hospital-acquired pneumonia in an open controlled trial. The drug was administered in a dose of 3.1 g every 4 or 6 hours depending on the infection severity. When pneumonia was due to Pseudomonas aeruginosa, amikacin was additionally used. The positive clinical effect of ticarcillin/clavulanate was stated in 73 per cent of the patients. The pathogen eradication was stated in all the patients. However, in 2 cases superinfection due to P.aeruginosa developed. Mild adverse effects were observed in 2 cases. It is concluded that ticarcillin/clavulanate is highly efficient in the treatment of patients with severe or complicated pneumonia. In cases with ventilator-associated pneumonia it is advisable to use ticarcillin/clavulanate in combination with an aminoglycoside.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing and Associated with Urinary Tract Infections in Malaysia.
Antibiotics (Basel)
February 2021
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.
The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing has greatly affected the clinical efficacy of β-lactam antibiotics in the management of urinary tract infections (UTIs). The limited treatment options have resulted in the increased use of carbapenem. However, flomoxef could be a potential carbapenem-sparing strategy for UTIs caused by ESBL-producers.
View Article and Find Full Text PDFLongitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Species from Cystic Fibrosis Patients.
Antimicrob Agents Chemother
October 2020
Department of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
spp. are recognized as emerging pathogens in patients with cystic fibrosis (CF). Though recent works have established species-level identification using sequencing, there is a dearth in knowledge relating to species-level antimicrobial susceptibility patterns and antimicrobial combinations, which hampers the use of optimal antimicrobial combinations for the treatment of chronic infections.
View Article and Find Full Text PDFEvaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
PLoS One
July 2016
Department of Respiratory Diseases, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
Background: The optimal therapy for infections caused by Stenotrophomonas maltophilia (S. maltophilia) has not yet been established. The objective of our study was to evaluate the efficacy of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, polymyxin E, chloramphenicol, and ceftazidime against clinical isolated S.
View Article and Find Full Text PDFA Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
Am J Respir Crit Care Med
December 2015
1 Department of Intensive Care Medicine.
Rationale: Continuous infusion of β-lactam antibiotics may improve outcomes because of time-dependent antibacterial activity compared with intermittent dosing.
Objectives: To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis.
Methods: We conducted a randomized controlled trial in 25 intensive care units (ICUs).
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance.
Front Microbiol
December 2013
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center Cleveland, OH, USA ; Department of Medicine, Case Western Reserve University Cleveland, OH, USA ; Pharmacology, Case Western Reserve University Cleveland, OH, USA ; Molecular Biology and Microbiology, Case Western Reserve University Cleveland, OH, USA.
The increasing incidence and prevalence of multi-drug resistance (MDR) among contemporary Gram-negative bacteria represents a significant threat to human health. Since their discovery, β-lactam antibiotics have been a major component of the armamentarium against these serious pathogens. Unfortunately, a wide range of β-lactamase enzymes have emerged that are capable of inactivating these powerful drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!